PT-141 (Bremelanotide): What the Published Research Reports

PT-141, known in the literature as bremelanotide, is a cyclic heptapeptide melanocortin receptor agonist that has been characterized across structural, preclinical, and clinical research settings [1][3]. Cryo-electron microscopy work resolved full-length melanocortin-4 receptor (MC4R) in complex with heterotrimeric Gs protein bound to the endogenous peptide α-MSH, to afamelanotide, to bremelanotide, and to a small-molecule ligand, describing a conserved binding mode for peptidic agonists and an activation mechanism distinct among melanocortin receptors; this work was conducted in vitro using purified receptor complexes and cell-based pharmacology [1]. A review of melanocortin receptor ligands classified bremelanotide among the clinically approved agonists at the neural melanocortin receptors MC3R and MC4R, alongside setmelanotide and ACTH, and summarized in vitro receptor pharmacology for this ligand class [2]. Mechanistic framing in the literature centers on the hypothalamus. A neurobiology review reported that bremelanotide non-selectively activates several melanocortin receptor subtypes, with MC4R described as the most relevant subtype at the concentrations studied, and that MC4R is predominantly expressed in the medial preoptic area of the hypothalamus; the review cited animal studies proposing that activation of presynaptic MC4R in that region increases dopamine release [3]. An earlier review of melanocortins in sexual function summarized findings that systemic administration of the α-MSH analog MT-II produced penile erection across several species and that bremelanotide and related melanocortinergic compounds showed erectogenic activity attributed to central melanocortin receptor binding, together with animal-model observations of pre-copulatory behaviors in female rats [4]. A more recent study in female Syrian hamsters examined melanocortin receptor mRNA distribution and reported that most MC3R and MC4R mRNA in the ventral tegmental area localized to dopamine neurons, that MC4R in the nucleus accumbens was expressed largely in interneurons rather than D1- or D2-receptor neurons, and that bremelanotide treatment did not alter melanocortin receptor mRNA expression in the mesolimbic dopamine system and did not enhance sexual reward in a conditioned place preference test; the authors concluded that the compound does not appear to act through the VTA–nucleus accumbens reward circuit in this animal model [5]. Early clinical development of the compound spanned both male and female populations. A review covering melanocortin receptor agonists, including melanotan I, melanotan II, and bremelanotide, summarized basic and clinical research on this class in male erectile dysfunction and in female arousal and orgasmic disorders in human studies [6]. A randomized, double-blind, placebo-controlled trial in 342 men with erectile dysfunction who had not responded to sildenafil compared intranasal bremelanotide with placebo and reported positive clinical results in 33.5% of the bremelanotide group versus 8.5% of the placebo group (p = 0.03), higher intercourse satisfaction domain scores in the active group, and more drug-related adverse effects in the active group (p = 0.01) [7]. Subsequent human trials focused on premenopausal women with hypoactive sexual desire disorder (HSDD). A phase 2b dose-ranging study reported responder analyses across seven patient-reported endpoints, with minimal clinically important differences derived from expert anchors, self-reported global benefit, receiver operating characteristic curves, and cumulative distribution functions; responder rates at the subcutaneous dose later carried into registration trials reached statistical significance versus placebo for all seven endpoints (p ≤ .03) in this human population [8]. The two identically designed phase 3 RECONNECT trials randomized 1,267 premenopausal women and reported statistically significant increases from baseline in the Female Sexual Function Index desire domain and statistically significant reductions in the Female Sexual Distress Scale–Desire/Arousal/Orgasm item 13 relative to placebo in both studies and in the integrated analysis, with nausea, flushing, and headache reported in 10% or more of participants in both trials [9]. A 52-week open-label extension of RECONNECT enrolled 684 of 856 eligible participants, of whom 272 completed; the most common treatment-emergent events considered related to study drug were nausea (40.4%), flushing (20.6%), and headache (12.0%), and the authors reported no new safety signals over that period in this human cohort [10]. Prespecified and integrated subgroup analyses of 1,202 RECONNECT participants reported statistically significant changes in desire and distress measures versus placebo across age, weight, body mass index, and baseline bioavailable testosterone quartile subgroups, with few exceptions, and across strata defined by hormonal contraceptive use, concurrent decreased arousal, and HSDD duration [11]. An integrated safety review across the clinical development program described 43 completed studies comprising 3,500 human subjects from phase 1 through phase 3 [12]. In the integrated double-blind phase 3 population (N = 1,247), the most common adverse events in the bremelanotide versus placebo groups were nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%), headache (11.3% vs 1.9%), and injection site reactions (5.4% vs 0.5%), with nausea the most frequent reason for discontinuation [12]. That review also reported no deaths, rare focal hyperpigmentation when dosing followed label recommendations but hyperpigmentation in more than one-third of subjects after up to 16 consecutive daily administrations, small transient but statistically significant blood pressure increases on ambulatory monitoring, and drug–drug interactions that lowered plasma concentrations of indomethacin and naltrexone [12]. Several narrative reviews place this evidence in context. A pharmacotherapy review of premenopausal HSDD identified bremelanotide and flibanserin as the two agents approved for generalized acquired HSDD in premenopausal women and advised caution in interpreting the human trial record, citing limited efficacy magnitude, adverse effects, and transparency issues in reporting [13]. A review of serotonergic mechanisms in female HSDD described melanocortins among the excitatory neuromodulators of sexual response and listed bremelanotide among centrally acting agents investigated for this indication in human trials [14]. Broader reviews of HSDD etiology and diagnosis discuss bremelanotide among newer pharmacologic options alongside flibanserin and integrative approaches in human clinical practice [15], as do reviews of sexual dysfunction in premenstrual dysphoric disorder [16] and of sexual health after breast and gynecologic cancer [17]. A methodological review of baseline data from published randomized placebo-controlled HSDD trials — including testosterone, flibanserin, and bremelanotide studies — reported that women enrolled with documented HSDD engaged in sexual activity approximately 2.5 times per month at baseline, which the authors argue has implications for sample-size calculation and for interpreting satisfying sexual events as a primary endpoint in human trials [18]. Two further strands of research concern formulation and analysis rather than physiology. A delivery study developed a biodegradable buccal suction patch and reported, in beagle dogs, a relative bioavailability of 26% for bremelanotide (1.03 kDa) compared with subcutaneous administration, with supporting permeation data from an ex vivo porcine buccal tissue model [19]. An analytical study developed a stability-indicating RP-HPLC method for bremelanotide acetate and characterized eight degradation products by LC-HRMS/MS after forced degradation under acidic, basic, neutral hydrolytic, oxidative, thermal, and photolytic stress; the reported major degradation pathways were deacetylation, peptide-bond hydrolysis, oxidation, and epimerization, with stereochemical sites predicted by computational energy minimization, all conducted in vitro [20].